MRGX Receptor Antagonists

Publication: US2021128561A1
Published: 2021-05-06
Family Size: 1
Granted: No

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to compounds that block the MrgX2 receptor, as well as their physiologically acceptable salts. Such compounds can be used in pharmaceutical compositions to prevent or treat diseases or disorders related to the MrgX2 receptor.

Use CasesContent extracted from patent full text and abstract with AI.

  • Treatment of allergic diseases involving abnormal mast cell activation
  • Therapy for chronic itchy skin conditions (pruritus) where MrgX2 is implicated
  • Developing medications for asthma or other inflammatory diseases associated with the MrgX2 pathway
  • Preventing adverse reactions caused by certain drugs via mast cell activation through MrgX2

BenefitsContent extracted from patent full text and abstract with AI.

  • Provides a targeted approach for diseases associated with the MrgX2 receptor
  • May reduce side effects compared to less selective treatments
  • Potential to treat currently untreatable or difficult-to-treat chronic conditions
  • Improves quality of life for patients with allergic or inflammatory disorders

Technical Classifications (CPCs)

Main Classifications

Health, Food & Consumer Tech

Sub Classifications

Medical & Vet Science

CPC Codes

A61K31/519A61K31/542

Inventors & Applicants

Applicants

Univ Bonn Rheinische Friedrich Wilhelms

Univ Leuven Kath

Patent Abstract

The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist.

Key Information

Publication No.

US2021128561A1

Family ID

75688259

Publication Date

2021-05-06

Application No.

US201916670149A

Application Date

2019-10-31

Priority Date

2019-10-31

Granted

No

Possible Cooperation

For further information please contact the transfer office.